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Abstract
Background: Depression is known to increase the risk for coronary heart disease (CHD) likely through various
pathogenetic actions. Understanding the links between depression and CHD and the effects of mediating
these links may prove beneficial in CHD prevention.
Methods: An integrated model of CHD was used to elucidate pathogenetic pathways of importance between
depression and CHD. Using biomarker relative risk data the pathogenetic effects are representable as measurable
effects based on changes in biomarkers.
Results: A ‘connection graph’ presents interactions by illustrating the relationship between depression and the
biomarkers of CHD. The use of selective serotonin reuptake inhibitors (SSRIs) is postulated to have potential to
decrease CHD risk. Comparing the ‘connection graph’ of SSRI’s to that of depression elucidates the possible
actions through which risk reduction may occur.
Conclusions: The CHD effects of depression appear to be driven by increased inflammation and altered
metabolism. These effects might be mediated with the use of SSRI’s.
Background
Depression is one of several preventable causes of
disability worldwide, with coronary heart disease (CHD)
being the largest cause of disability [1]. In addition,
CHD is also the largest cause of death globally [2].
There is an established link between these two disor-
ders, where depression has been noted as a risk factor
for CHD [3] and patients with established CHD have
been found to have increased incidence of depression
compared to controls [4]. Depressed CHD patients are
significantly linked to increased mortality [5] and poor
prognosis for further CHD events [6]. Depressed pa-
tients using antidepressants appear to be at a reduced
risk for CHD. However, the mechanisms behind this
reduced risk are not clear [7].
To gain more insight into associations between depres-
sion, antidepressants, and CHD an integrated model of
CHD pathogenesis, health factors, biomarkers and phar-
macotherapeutics would be beneficial [8]. We can then
consider the effect of treatment of depression with antide-
pressants on the pathogenesis of CHD. This will help with
insight as to how antidepressants might decrease CHD
risk in the depressed.
Methods
Health factor integration with CHD
Our integrated model was developed and described in a
previous article [9]. Briefly, a systematic review of the
literature from after 1998 and including highly cited
papers was conducted for CHD pathogenesis, health
factors, biomarkers and pharmacotherapeutics. This re-
search was combined to develop the integrated model
of CHD [9].
The health factors in the integrated model were con-
sidered as lifestyle effects or comorbid health disorders
which have been associated with statistically significant
increases or decreases in CHD risk. The pharmaceuticals
in the integrated model were those whose use has been
associated with statistically significant decreases in CHD
risk in primary or secondary prevention.
The biomarkers considered for the integrated model
were mainly those whose measurement has been associ-
ated with statistically significant increases or decreases in* Correspondence: mjmathews@rems2.com
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CHD risk. However, some biomarker data was included
where results have not been statistically significant as an
emphasis of their lack of prediction ability.
The above components were combined to develop the
integrated model [9] which will be used in this article to
describe the interconnections of depression on the patho-
genesis of CHD. We attempt to quantify the CHD effect
of depression and antidepressants by the effect thereof on
an array of biomarkers which represent increasing or
decreasing CHD risk. The study dealt mainly with the
primary prevention aspects as most of the data gathered
for the effects of SSRI use on the biomarkers was from
studies in patients without CHD.
Statistical analysis
It must be noted that some of the RR values in this art-
icle are presented in a manner which differs from con-
vention [9]. The need for this comes as a result of the
visual scaling of the traditional RR. Traditionally, if one
plots an RR = 3 and RR = 0.33, respectively, the one does
not ‘look’ three times worse and the other three times
better than the normal RR = 1. The reason is that the
scales for the positive and negative effects are not nu-
merically similar. A graph of ‘good’ and ‘bad’ RR can
therefore be deceptive for the untrained person, e.g., a
patient.
This article rather uses the method that the conven-
tional RR = 3 is three times worse than the normal RR = 1.
While the conventional RR = 0.33 means that the pa-
tient’s position is three times better than the normal
RR = 1. Thus, in summary: a conventional RR = 3 is pre-
sented as per normal, as a 3-fold increase in risk and a
conventional RR = 0.33 is presented as a 3-fold decrease
in risk (1/0.33 = 3).
Results
Integrated model
The integrated model in Fig. 1 schematically illustrates
the complexity of CHD and shows all theoretical patho-
genetic pathways between the health factors and CHD.
The health factors that are described by the integrated
model include both modifiable lifestyle effects and under-
lying comorbid disorders such as depression. A more
detailed discussion of Fig. 1, relevant to depression, is
given in next section.
The pathways (pathogenesis of CHD) within the inte-
grated model can be tracked from where a chosen health
factor influences the relevant tissue, to the end state of
CHD. This will be conducted for depression in the fol-
lowing section of this study. The pathways presented in
Fig. 1 are a visual representation of previously published
knowledge. Salient serological biomarkers (shown in
Fig. 1 as ) and pharmacotherapeutics (shown in Fig. 1
as ) that act on the pathways are further indicated in
Fig. 1.
Pathogenetic effects of depression
In order to appraise the CHD effects of depression, the
relevant pathogenetic pathways need to be considered.
While Fig. 1 also indicates other health factors, only the
pathways activated by depression, presented in Fig. 1,
are summarized in Table 1. It is important to note that
not all of the pathways will be relevant to every patient
and that all the pathways may not be active simultan-
eously, or occur in the same patient.
Some of the pathological effects of depression on
CHD are thought to be mediated by the over stimulation
of the hypothalamic-pituitary-adrenocortical (HPA) axis
[10]. Increased levels of corticotropin-releasing factor
(CRF) and its stimulation of the production and release
of adrenocorticotropic hormone (ACTH), mediates the
activation of the HPA axis [11]. This can lead to increased
plasma cortisol levels [12]. The overstimulation of the
HPA axis may augment sympathoadrenal (SA) hyperactiv-
ity via central regulatory pathways, resulting in increased
plasma catecholamines [13], such as norepinephrine, epi-
nephrine and dopamine [14].
Chronic dysregulation of the HPA axis, such as in
depression, can lead to chronically increased serum
levels of cortisol [12], which can have negative effects on
insulin and blood glucose levels [15]. The effect of corti-
sol on blood glucose is shown in the integrated model
(Fig. 1) through pathway 7-27-48-14-blood glucose-55-
hyperglycaemia, with the possibility that over stimulation
of the pathway could lead to the CHD hallmark of
hyperglycaemia.
Further, abnormalities in blood glucose control and
insulin sensitivity are seen in patients with major de-
pressive disorder, even in individuals who are non-
obese and not diabetic [16]. Some of these effects may
be explained by the increased secretion of glucocorti-
coids, which oppose the effects of insulin and increases
the turnover between stored energy, in the form of
glycogen, triglycerides and protein, and freely available
fuel for mitochondrial oxidation, in the form of glucose
and free fatty acids [17]. This serves to increase blood
glucose levels. Blood glucose levels can also be in-
creased, by glucocorticoids, through an effect on hep-
atic gluconeogenesis and insulin secretion [15]. (Fig. 1,
Pathway: 7-27-48-14-55-hyperglycaemia).
Pathways: 6-27-47 and 7-26-44 in the integrated model
(Fig. 1) show how catecholamines and glucocorticoids
inhibit insulin actions and thus contribute to insulin
resistance [18, 19]. Additionally, it is possible for insulin
resistance to occur due to inhibition of the phos-
phatidylinositol 3-kinase (PI3K) insulin signaling pathway
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or the stimulation of the MAPK pathway [20]. (Fig. 1, Path-
ways: 7-27-48-14-54-69-72-14-55- hyperinsulinaemia).
Elevated glucocorticoids can increase the responsiveness
to vasoconstrictors and reduce vasodilator production,
noted by a reduction in nitric oxide (NO) production or
bioavailability, contributing to glucocorticoid induced
hypertension [21]. (Fig. 1, Pathway: 7-27-48-14-53-57-
vasodilation).
Another possible mechanism underlying glucocorticoid
induced hypertension is shown in the integrated model
(Fig. 1) by pathway: 7-27-48-14-54-89-hypertension. This
details how depression could lead to increased activity of
the renin-angiotensin-aldosterone system, high leptin
levels and concurrent leptin resistance [22]. Furthermore
increased HPA axis activity can also increase oxidative
stress along with decreased antioxidant defenses [23],
Fig. 1 Conceptual model of general health factors, salient CHD pathogenetic pathways and CHD hallmarks. Note. From “How do high glycemic
load diets influence coronary heart disease?” by Mathews M, Liebenberg L, Mathews EH Nutr Metab 2015;12:6 [9]. The affective pathway of
pharmacotherapeutics, boxes, is shown in Fig. 1, and salient serological biomarkers are indicated by tags ( ). The blunted arrows denote
antagonize or inhibit and pointed arrows denote up-regulate or facilitate. ACE denotes angiotensin-converting-enzyme; BDNF, brain-derived
neurotrophic factor; β-blocker, beta-adrenergic antagonists; BNP, B-type natriuretic peptide; COX, cyclooxygenase; CRP, C-reactive protein; D-
dimer, fibrin degradation product D; FFA, free fatty acids; GCF, gingival crevicular fluid; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin
A1c; Hs, homocysteine; ICAM, intracellular adhesion molecule; IGF-1, insulin-like growth factor-1; IL, interleukin; LDL, low-density lipoprotein; MAPK,
mitogen-activated protein (MAP) kinase; MCP, monocyte chemoattractant protein; MIF, macrophage migration inhibitory factor; MMP, matrix me-
talloproteinase; MPO, myeloperoxidase; NFκβ, nuclear factor-κβ; NLRP3, Inflammasome responsible for activation of inflammatory processes as well
as epithelial cell regeneration and microflora; NO, nitric oxide; NO-NSAIDs, combinational NO-non-steroidal anti-inflammatory drug; OPG, osteo-
protegerin; oxLDL, oxidized LDL; P. gingivalis, Porphyromonas gingivalis; PAI, plasminogen activator inhibitor; PDGF, platelet-derived growth factor;
PI3K, phosphatidylinositol 3-kinase; RANKL, receptor activator of nuclear factor kappa-beta ligand; ROS, reactive oxygen species; SCD-40, recombin-
ant human sCD40 ligand; SMC, smooth muscle cell; SSRI, serotonin reuptake inhibitors; TF, tissue factor; TMAO, an oxidation product of trimethyla-
mine (TMA); TNF-α , tumor necrosis factor-α; vWF, von Willebrand factor; VCAM, vascular cell adhesion molecule
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which can lead to increased inflammation [24] as well as
lower brain derived neurotrophic factor (BDNF) activity
[25]. (Fig. 1, Pathway: 7-27-48-14-54-89-hypertension-
100-inflammatory state).
Increased insulin resistance can cause increased serum
levels of platelet factors and thus increases the potential
for hypercoagulability [26, 27]. Additionally, increased
insulin resistance has been found to be associated with
increased levels of inflammatory cytokine TNF-a and in-
creased levels of inflammation [28] as shown in the
integrated model in pathway: 7-27-48-14-54-69-70-88-
50-41-inflammatory state.
Elevations in glucocorticoids inhibit lipoprotein lipase
activity leading to diminished triglyceride clearance, de-
creased HDL concentrations, and increase in LDL
serum concentrations [29]. Additionally, high levels of
glucocorticoids suppress hepatic LDL receptors and
delay LDL clearance [30]. This shows how depression
can affect cholesterolaemia through pathways 7-27-
48-10-31-hypercholesterolaemia and 7-27-48-12-33-
51-hypercholesterolaemia.
The integrated model shows how depression may
affect coagulation and vasodilation through pathways:
7-26-catecholamines-44-73-hypercoagulability and 7-
Table 1 Putative effects of depression and salient CHD pathogenetic pathways
Pathways, and pathway numbers corresponding to those in Fig. 1 Refs.
a. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ platelet factors-73-↑ hypercoagulability a. [95–97]
b. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ NO depletion-57-↑ SMC proliferation b. [95]
c. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ NO depletion-57-↑ vasodilation c. [95]
d. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-70-↑ angiotensin II-89-↑ hypertension-100-↑ ROS-
85-↑inflammatory state
d. [95, 98–103]
e. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-70-↑ angiotensin II-88-50-↑ TNFα-41-↑ inflammatory
state
e. [44, 104–108]
f. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-70-↑ angiotensin II-89- ↑ SMC proliferation f. [95, 99, 101–103, 109]
g. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-70-↑ angiotensin II-89-↓ IGF1-↑ SMC proliferation g. [101–103, 109, 110]
h. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-72-↑ platelet factors-73-↑ hypercoagulability h. [17, 29, 99, 110–117]
i. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-72-14-55-↑ hyperglycaemia i. [110, 118–120]
j. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-12-↑ LDL-33-↑ oxLDL-51-↑ hypercholesterolaemia j. [29, 95, 121, 122]
k. 7-26-↑ catecholamines/↓ serotonin/↓ BDNF-44-↑ insulin resistance-70-↑ angiotensin II-89-↑ hypertension-100-↑ ROS-
85-↑ inflammatory state
k. [95, 106–108]
l. 7-27-↑ cortisol-48-10-↓ HDL-31-↑ hypercholesterolaemia l. [14, 17, 29, 99]
m. 7-27-↑ cortisol-48-12-↑ LDL-33-↑ oxLDL-51-↑ hypercholesterolaemia m. [14, 17, 29, 98, 99]
n. 7-27-↑ cortisol-48-14-↑ blood glucose-55-↑ hyperglycaemia n. [14, 17, 29, 99]
o. 7-27-↑ cortisol-48-14-↑ blood glucose-54-69-↑ insulin resistance-70-↑ angiotensin II-89-↑ hypertension-100-↑ ROS −85-
↑ inflammatory state
o. [98–100]
p. 7-27-↑ cortisol-48-14-↑ blood glucose-54-69-↑ insulin resistance-70-↑ angiotensin II-88-50-↑TNFα-41-↑ inflammatory
state
p. [123]
q. 7-27-↑ cortisol-48-14-↑ blood glucose-54-69-↑ insulin resistance-70-↑ angiotensin II-89-↑ SMC proliferation q. [99]
r. 7-27-↑ cortisol-48-14-↑ blood glucose-54-69-↑ insulin resistance-70-↑ angiotensin II-89-↓ IGF1-↑ SMC proliferation r. [101–103, 109]
s. 7-27-↑ cortisol-48-14-↑ blood glucose-54-69-↑ insulin resistance-72-↑ platelet factors-73-↑ hypercoagulability s. [17, 29, 99, 111–117]
t. 7-27-↑ cortisol-48-14-↑ blood glucose-54-69-↑ insulin resistance-72-↑ vasodilation t. [123]
u. 7-27-↑ cortisol-48-14-↑ blood glucose-54-19-↓ adiponectin-38-↑ TNFα-41-↑ P.gingivalis-43-↑ periodontitis-64-↑ platelet
factors-73-↑ hypercoagulability
u. [17, 29, 99, 111–117, 124]
v. 7-27-↑ cortisol-48-14-↑ blood glucose-54-19-↓ adiponectin-39-↑ insulin resistance- 72-↓ vasodilation v. [123]
w. 7-27-↑ cortisol-48-14-↑ blood glucose-54-19-↓ adiponectin-39-↑ SMC proliferation w. [125]
x. 7-27-↑ cortisol-48-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-72-14-55-↑ hyperinsulinaemia x. [17, 20, 29, 99]
y. 7-27-↑ cortisol-48-14-↑ blood glucose-53-↑ NO depletion-57-↑ SMC proliferation y. [17, 29, 99, 126]
z. 7-27-↑ cortisol-48-14-↑ blood glucose-53-↑ NO depletion-57-↓ vasodilation z. [17, 29, 99, 127]
aa. 7-27-↑ cortisol-48-14-↑ blood glucose-54-↑ angiotensin II-89-↑ hypertension-100-↑ ROS-85-↑ inflammatory state aa. [17, 29, 98, 99]
↑ denotes up regulation/increase, ↓ denotes down regulation/decrease, x-y-z indicates pathway connecting x to y to z
FFA free fatty acids, IGF 1 insulin-like growth factor-1, LDL low-density lipoprotein, MAPK mitogen-activated protein (MAP) kinase, NO nitric oxide, oxLDL oxidized
LDL, P. gingivalis Porphyromonas gingivalis, PI3K phosphatidylinositol 3-kinase, PI3K:MAPK ratio of PI3K to MAPK, ROS reactive oxygen species, SMC smooth
muscle cell, TNFα tumor necrosis factor-α
Mathews et al. BMC Cardiovascular Disorders  (2015) 15:82 Page 4 of 12
26-catecholamines-44-57-vasodilation. Elevated serum
levels of catecholamines, such as norepinephrine, may
promote hypercoagulability by platelet activation through
direct agonist effects, and endothelial injury by increased
hemodynamic stress on vascular walls [31].
Decreased levels of BDNF have been observed in
depressed patients [32, 33]. Normal or increased levels
of BDNF have been found to have positive effects on
some of the underlying pathogenesis of CHD including
improved glucose metabolism [34]. Thus a reduction
of BDNF can thus serve to reduce glucose control,
which can have a feedback effect by inhibiting the
cerebral output of BDNF [35] as shown in pathway: 7-
26-BDNF-44-72-14-55-hyperglycaemia.
However, BDNF may increase oxidative stress
through activation of NAD(P)H oxidase [36]. Thus
BDNF could have a negative impact on the pathogen-
esis of CHD and plaque stability. BDNF is thought to
positively affect the action and secretion of insulin,
ghrelin and leptin [34]. (Fig. 1, Pathway: 7-26-BDNF-
44-insulin resistance).
Increased levels of serotonin could serve to up-regulate
some of the underlying pathogenesis of CHD. Alterations
in serotonergic neuronal function in the central nervous
system occur in patients with major depression [37]. Acti-
vated platelets secrete serotonin in substantial quantities
which can cause vasoconstriction [38]. Additionally, sero-
tonin has a role in platelet aggregation and proliferation of
vascular endothelial cells [39, 40]. (Fig. 1, Pathways:
serotonin-94-57-SMC proliferation and serotonin-94-57-
vasodilation).
It is apparent that depression directly and indirectly
affects a plethora of interconnected pathogenetic mecha-
nisms. Each CHD hallmark and pathogenetic trait can
amplify the patient’s risk of CHD, thus necessitating an
integrated, multi-faceted therapeutic approach.
Biomarkers of coronary heart disease
While the pathogenesis of depression is not completely
understood, the possible pathogenetic effect of depres-
sion on CHD could be better understood through the
measurement of serological biomarkers [41]. Biomarkers
can be used as indicators of an underlying disorder. The
measurement of specific biomarkers enables the predic-
tion of the RR for CHD associated with the biomarker
[42–44]. This can allow for the quantification of the
effects of depression on the pathogenesis of CHD.
To simplify the integrated model, serological biomarkers
(which can be easily measured) are used to link the effect
of depression to the corresponding RR of CHD. Figure 2
presents a comparison of the RR associated with an array
of serological biomarkers per 1-standard deviation in-
crease in the biomarker [9].
Effects of depression on coronary heart disease
The pathogenesis of depression in CHD and the inte-
grated model in Fig. 1 could be used to account for the
impact that depression has on the serological biomarkers
of CHD (Fig. 2). The integrated model can be simplified
into a ‘connection graph’, which shows all the connec-
tions between depression and the serological biomarkers
of CHD without neglecting the underlying complexity of
CHD. The relevant pathways of Fig. 1 are shown on the
connection lines of Fig. 3.
For further clarity the biomarkers previously shown in
Fig. 2 were divided into eight classes. Furthermore, the
connection lines are scaled according to the RR associ-
ated with the biomarker. Thus, the greater the RR for
CHD of a biomarker the thicker the connection line will
be to that biomarker. For example, the RR for CHD as-
sociated with leptin is relatively low, thus the connection
line between depression and leptin is thin. The RR for
CHD associated with insulin resistance is large thus the
connection line between depression and insulin resist-
ance is thick.
While the connection lines give an indication of which
biomarkers of CHD are affected by depression they do
not indicate the nature of the connection. The effect of
the connection are thus shown by arrows in Fig. 3 which
indicate whether the effect on the biomarker is to
increase (↑) or decrease risk (↓).
The interconnectedness of depression is immediately
evident from Fig. 3. Depression is seen to have connec-
tions to the vast majority of the CHD biomarkers consid-
ered here. It is evident that depression is widely connected
to inflammatory and metabolic biomarkers. Additionally,
there are connections between all the lipid biomarkers
and some of the markers of vascular function, oxidative
stress and coagulation.
Increased levels of inflammation have been reported in
patients with depression [45, 46]. It has even been sug-
gested that increased inflammatory markers may be a risk
factor for the progression of depression [45]. Increased
levels of inflammatory markers such as the cytokines CRP,
IL-6 and TNF-α have been measured in patients with
depression [47, 48], regardless of a causal link between
depression and inflammation.
Changes in osteoprotegerin may be possible due to the
observation of decreased bone density [49] and an in-
creased risk of osteoporosis in depressed patients [50].
Thus inflammation and depression seem intertwined and
could account for some of the increased CHD risk due to
depression.
Many of the metabolic aspects of depression could be
mediated through the actions of cortisol and BDNF. In-
creased serum levels of cortisol have been noted in de-
pressed patients [12, 51], and may lead to other metabolic
complications such as hyperglycaemia, hyperinsulinaemia
Mathews et al. BMC Cardiovascular Disorders  (2015) 15:82 Page 5 of 12
and hypercholesterolemia. Thus, BDNF and cortisol may
possibly explain the link between depression and glycated
hemoglobin (HbA1c), insulin resistance, LDL and HDL
[15, 19, 29].
BDNF has frequently been found to be reduced in
patients with depression with the implication being that
reduced levels of BDNF may be a suitable biomarker for
depression [52]. Beyond this intriguing possibility for its
use as a biomarker for depression it is postulated here
that reduced levels of BDNF may also be a suitable pro-
spective biomarker for CHD risk. This is indicated by the
dashed bar in Figs. 2 and 3 [53].
Adiponectin levels in patients with depression have
been found to be lower than that of healthy controls
independent of conventional factors such as coronary
heart disease and metabolic disorders [54]. This could
imply that lowered adiponectin levels associated with
depression could indicate increased risk for CHD.
The connection between depression and the lipid bio-
markers is not as clear as between depression and in-
flammation [55]. Conflicting evidence surrounds the
association between depression and cholesterol levels.
Some studies have found that HDL, LDL and Apo B
levels are increased in patients with depression [56],
others have found that depression is associated with
decreased HDL and increased LDL levels [57], yet
others have found that both LDL and HDL decrease
with depression [55]. Regardless of the unknown effect
between cholesterol and depression it is evident that
there may be some connection between the two.
The effect of depression on other lipid biomarkers
such as leptin are also not clearly elucidated as both
increased [58] and decreased levels have been noted in
patients with depression [59]. Some of the changes in
leptin may be mediated to some degree by decrease in
BDNF which are observed in depression [60].
The impact of depression on vascular function may be
mediated by increased serum levels of homocysteine and
B-type natriuretic peptide (BNP) which are evident in
patients with major depressive disorder [61, 62]. In-
creased serum levels of homocysteine and BNP are both
associated with an increased risk of CHD [63, 64]. This
indicates a possible connection between depression and
CHD through an underlying vascular action.
A connection may exist between depression and both
oxidative stress and coagulation in the increased levels
of serum myeloperoxidase (MPO) and fibrinogen re-
spectively [47, 48]. Thus it is evident that the use of
biomarkers may further elucidate the connections be-
tween underlying pathogenesis which may be common
Fig. 2 Normalized relative risks (fold-change) of salient current biomarkers or of potential serological biomarkers for CHD. Note. From “How do
high glycemic load diets influence coronary heart disease?” by Mathews M, Liebenberg L, Mathews EH Nutr Metab 2015;12:6 [9]. Increased IGF-1
and HDL levels are associated with a moderately decreased CHD risk. (IGF-1 and HDL levels are significantly inversely correlated to relative risk for
CHD.) N indicates number of trials; I, standard error; ACR, albumin-to-creatinine ratio; Adipo, adiponectin; ApoB, apolipoprotein-B; BDNF, brain-
derived neurotrophic factor; BNP, B-type natriuretic peptide; Cort, cortisol; CRP, C-reactive protein; Cysteine, Homocysteine; Fibrin, fibrinogen; GDF-
15, growth-differentiation factor-15; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; IL-6, interleukin-6; IGF-1, insulin-like growth
factor-1; LDL, low-density lipoprotein; MPO, myeloperoxidase; RANKL or OPG, osteoprotegerin; TNF-α, tumor necrosis factor-α; Trop, troponins;
Trigl, triglycerides
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between both depression and CHD. This may help un-
derstanding the relationship between depression and
the increased risk for CHD.
Antidepressants
To attempt to elucidate the effects of antidepressant
treatment of depression on the pathogenesis of CHD the
integrated model in Fig. 1 was used to formulate a ‘con-
nection graph’ for the use of selective serotonin reuptake
inhibitor (SSRI) antidepressants. SSRI’s were chosen as
they have been linked to greater likelihood of positive
outcome after CHD event [65]. Furthermore, certain
other antidepressants, such as tricyclic antidepressants,
have been linked to increased incidence of adverse CHD
outcomes [66].
The serological biomarkers which are modified by use
of SSRI’s are presented in Fig. 4. Figure 4 is a ‘connection
graph’ presented in the same manner as was Fig. 3. The
‘connection graph’ for SSRI antidepressants elucidates
known changes in serological biomarkers. The paths upon
which SSRI’s may act to influence these biomarkers are
indicated on the connection lines.
The serum levels of CRP and IL-6 have been ob-
served to be reduced by SSRI use in the depressed [67].
Tumor necrosis factor-α (TNF-α) may play a role in
the responsiveness of SSRI use, with increased levels
predicting non-responsiveness [68]. The modification
of these biomarkers by SSRI’s could serve to decrease
the risk for CHD. Osteoprotegerin is decreased by the
use of some SSRI’s [69], which may serve to decrease
the risk of CHD. SSRI’s affect the entire range of in-
flammatory biomarkers in a manner that would suggest
CHD risk decreases.
The metabolic links between CHD and SSRI’s are most
likely mediated by the effect of increased BDNF levels
after SSRI treatment [51, 52]. SSRI’s also have an effect
on insulin like growth factor 1 (IGF-1) which is low in
children using SSRI’s [70] and interruption of SSRI treat-
ment leads to increased serum levels thereof [71].
Increased insulin sensitivity, which has been noted in
patients who have remitted depression using SSRI’s [72],
could also serve to positively affect serum glucose levels.
Increased adiponectin levels have been found to occur
due to, inhibition of TNF-α production, after remittance
of depression [73].
Fig. 3 Interconnection of relative risk effects of depression and serological biomarkers for CHD. ACR denotes, albumin-to-creatinine ratio; Adipon,
adiponectin; ApoB, Apolipoprotein-B; BDNF, brain-derived neurotrophic factor; BNP, B-type natriuretic peptide; Cort, cortisol; CRP, C-reactive pro-
tein; Cysteine, Homocysteine; Fibrin, fibrinogen; GDF-15, growth-differentiation factor-15; HbA1c, glycated hemoglobin A1c; HDL, high-density
lipoprotein; IGF-1, insulin-like growth factor-1; IL-6, interleukin-6; LDL, low-density lipoprotein; MPO, myeloperoxidase; RANKL or OPG, osteoproteg-
erin; TNF-α, tumor necrosis factor-α; Trigl, triglycerides; Trop, troponins
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Cortisol levels have been recorded as both increased
[67, 74], and decreased [75] in patients using SSRI’s, thus
a possible link exists between SSRI use and serum corti-
sol levels. However, as a whole the effect of SSRI’s on
the metabolic biomarkers would appear to be positive,
as shown in Fig. 4. The “connection graph” suggests that
the effect of SSRI’s on the metabolic biomarkers is such
that it would reduce CHD risk.
The connections between SSRI antidepressants and the
lipid biomarkers, shown in Fig. 4, are due to increased
serum levels of LDL and HDL cholesterol noted in
patients treated with SSRI’s [76, 77]. Current research has
shown that serum ghrelin levels can be normalized [78]
which could lead to changes in eating habits and thereby
affect leptin levels [79]. The net effects of SSRI’s on the
lipid profile, in terms a patients risk for CHD, may be
somewhat uncertain. This is due to the positive changes in
HDL levels, negative changes in LDL levels, no substantial
change in leptin levels and an unknown effect on Apo B.
Figure 4 shows the improvements of oxidative stress
which may be possible with SSRI [80]. These changes in
oxidative stress may be present in patients as changes in
MPO serum levels [81]. Furthermore, Fig. 4 shows how
serum levels of fibrinogen can be reduced by SSRI use
[67]. These changes would present a lower risk for CHD
according to biomarker RR prediction.
Unfortunately the fully quantified effect of the differ-
ent biomarkers, modified by SSRI use, is not shown by
the “connection graph” in Fig. 4. The “connection graph”
only shows if a biomarker is affected and if this effect is
positive or negative. Future studies will be required to
quantify the effect of each biomarker individually on the
risk for CHD. Furthermore when considering the impli-
cations of antidepressant use on the biomarkers of CHD
it is important to note that antidepressants would likely
only prove beneficial in patients with depression and not
in the general population [65, 82].
It must be noted that like all pharmacotherapeutic ther-
apies there is always the possibility for some adverse
effects [83–85] and possible drug interactions [86]. How-
ever, SSRI treatment has proved to be both safe and effect-
ive in treating depression in patients with CHD [87].
Fig. 4 Interconnection of relative risk effects of selective serotonin reuptake inhibitor use and serological biomarkers for CHD. ACR denotes,
albumin-to-creatinine ratio; Adipon, adiponectin; ApoB, Apolipoprotein-B; BDNF, brain-derived neurotrophic factor; BNP, B-type natriuretic peptide;
Cort, cortisol; CRP, C-reactive protein; Cysteine, Homocysteine; Fibrin, fibrinogen; GDF-15, growth-differentiation factor-15; HbA1c, glycated
hemoglobin A1c; HDL, high-density lipoprotein; IGF-1, insulin-like growth factor-1; IL-6, interleukin-6; LDL, low-density lipoprotein; MPO, myeloper-
oxidase; RANKL or OPG, osteoprotegerin; TNF-α, tumor necrosis factor-α; Trigl, triglycerides; Trop, troponins
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Discussion
The ‘connection graph’ for depression presented in
Fig. 3 indicates that the effect of depression on CHD
pathogenesis, as measured by effects on serological
biomarkers of CHD, would likely serve to increase a
depressed patients risk for CHD. The magnitude of this
effect can be quantified through determining the RR for
CHD offered by depression.
Observational studies considering the incidence of
CHD in depressed patients may provide these answers.
A meta-analysis of such studies comprising 124,509
patients in 21 studies found that the depressed had an
increased RR for CHD of 1.90 (1.49 to 2.42) compared
to healthy controls [4].
It is known that antidepressants such as SSRI’s can
mediate the symptoms of depression [88] and impact
the biomarkers of CHD in such a manner that would
appear to be positive in terms of CHD risk (Fig. 4).
Again the magnitude of this effect is evident in the poten-
tial reduction in CHD risk due to SSRI’s use in a depressed
population initially without CHD [7].
In an observational study of 93,653 patients with
depression, without CHD, it was found that patients,
who had 12 or more weeks of antidepressant treatment,
had a RR for CHD of 0.48 (0.44 to 0.52) compared to
patients not treated. When using our risk presentation
this equates to a possible 2.08-fold reduction in CHD
risk. The observational nature of this study must be noted
and conclusions on treatment cannot be directly drawn
from these results. The results may allude to primary pre-
vention of CHD due to SSRI use in the depressed [7].
Some of the important aspects of depression may be
the increase in inflammation and dysregulation of me-
tabolism evident through the increases in inflammatory
and metabolic biomarkers [15, 47, 48, 89]. Comparing
the ‘connection graphs’ of depression and SSRI use it is
clear that some of the manners in which depression ef-
fects the serological biomarkers are mediated by SSRI’s.
These effects include positive impacts on coagulation,
oxidative stress and metabolism which are deregulated
by depression. The effects of depression on lipids are
not wholly clear (Fig. 3) and accordingly the effects of
SSRI’s on these would most likely not account for the
decreased risk observed (Fig. 4).
Interestingly the inflammatory biomarkers which are
all negatively influenced by depression are positively me-
diated by SSRI usage. This may highlight the importance
of inflammation in the pathogenesis of CHD especially
in how depression influences it. A combination of these
changes presents the possible action of a risk reduction,
such as those observed in depressed patients using
SSRI’s [7].
The data from Fig. 3 and Fig. 4 show that inflamma-
tion and metabolic dysregulation may be key aspects in
the pathogenesis of CHD [15, 45, 46, 90]. These aspects
increase in depression and may play a part in the 1.90-
fold increased risk for CHD. With the use of SSRI anti-
depressants these factors decrease and may present up
to a 2.08-fold reduction in CHD risk. This further high-
lights the importance of inflammation and metabolic
dysregulation the pathogenesis of CHD.
Depression not only has direct effects but can have
further negative effects on the treatment and secondary
prevention of CHD. Depressed patients typically have
trouble adhering to medication and intervention therapy
[91]. This could serve to explain some of the increased
risk that is associated with depression after a CHD event
[92]. These and direct actions of depression on CHD
adds credence to the recommendation that depression
should be elevated to the status of risk factor for poor
prognosis in patients with CHD [93].
Based on the evidence we believe that the CHD risk
associated with depression is substantial and should
garner a similar level of public interest as does other
risk factors such as smoking, high cholesterol and treat-
ments such as statin therapy. We agree very strongly with
recommendations presented by the American Heart Asso-
ciation that depression should be screened for regardless
of a causal link between improved depression and CHD
risk [94].
Further research is required in the form of adequately
powered interventional trials on the efficacy of SSRI’s in
primary prevention of CHD in depressed patients. Add-
itionally, studies are required to determine the risk for
CHD that would be associated with decreased serum
levels of BDNF.
Conclusions
It is apparent that depression has a wide ranging impact
on the pathogenesis of CHD with these effects notable in
changes in CHD biomarkers. However, depression can be
mediated through the use of antidepressants such as
SSRI’s. These antidepressants may mediate some of the
negative pathogenetic effects of depression on CHD. Such
effects are noted in the normalization of the CHD bio-
markers in patients using SSRI’s. These effects result in a
decreased risk for CHD observed in depressed patients
using SSRI antidepressants.
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